Chruściel Elżbieta, Urban-Wójciuk Zuzanna, Arcimowicz Łukasz, Kurkowiak Małgorzata, Kowalski Jacek, Gliwiński Mateusz, Marjański Tomasz, Rzyman Witold, Biernat Wojciech, Dziadziuszko Rafał, Montesano Carla, Bernardini Roberta, Marek-Trzonkowska Natalia
International Centre for Cancer Vaccine Science (ICCVS), University of Gdańsk, 80-309 Gdańsk, Poland.
Department of Pathomorphology, Medical University of Gdańsk, 80-210 Gdańsk, Poland.
Cancers (Basel). 2020 Mar 13;12(3):683. doi: 10.3390/cancers12030683.
In recent years, much research has been focused on the field of adoptive cell therapies (ACT) that use native or genetically modified T cells as therapeutic tools. Immunotherapy with T cells expressing chimeric antigen receptors (CARs) demonstrated great success in the treatment of haematologic malignancies, whereas adoptive transfer of autologous tumour infiltrating lymphocytes (TILs) proved to be highly effective in metastatic melanoma. These encouraging results initiated many studies where ACT was tested as a treatment for various solid tumours. In this review, we provide an overview of the challenges of T cell-based immunotherapies of solid tumours. We describe alternative approaches for choosing the most efficient T cells for cancer treatment in terms of their tumour-specificity and phenotype. Finally, we present strategies for improvement of anti-tumour potential of T cells, including combination therapies.
近年来，许多研究聚焦于过继性细胞疗法（ACT）领域，该疗法使用天然或基因改造的T细胞作为治疗工具。嵌合抗原受体（CAR）修饰的T细胞免疫疗法在血液系统恶性肿瘤治疗中取得了巨大成功，而自体肿瘤浸润淋巴细胞（TIL）的过继性转移在转移性黑色素瘤治疗中被证明非常有效。这些令人鼓舞的结果引发了许多研究，其中ACT被作为各种实体瘤的治疗方法进行测试。在本综述中，我们概述了实体瘤基于T细胞免疫疗法面临的挑战。我们描述了根据肿瘤特异性和表型选择最有效T细胞用于癌症治疗的替代方法。最后，我们介绍了提高T细胞抗肿瘤潜力的策略，包括联合疗法。
